# Insulet Corporation

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Insulet Corporation).

## Overview

Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes. Its core business is replacing multiple daily injections and traditional tubed pumps with wearable, disposable pod-based insulin delivery, supported by training, customer support, reimbursement, and billing services.

## Products & services

• Omnipod 5 automated insulin delivery system
• Omnipod DASH insulin management system
• Disposable insulin pods and related supplies
• Diabetes onboarding, training, and customer support
• Reimbursement, insurance, and billing support
• Drug delivery pods for Amgen's Neulasta Onpro kit

- **Omnipod insulin delivery systems** (99%) — Tubeless wearable insulin delivery platforms, including Omnipod 5 and Omnipod DASH.
- **Pods and consumables** (1%) — Recurring disposable pods and related supplies used with the Omnipod platform.
- **Drug Delivery** (1%) — Pods sold to Amgen for use in the Neulasta Onpro delivery kit.

- Omnipod 5 automated insulin delivery system
- Omnipod DASH insulin management system
- Disposable insulin pods and related supplies
- Diabetes onboarding, training, and customer support
- Reimbursement, insurance, and billing support
- Drug delivery pods for Amgen's Neulasta Onpro kit

## Customers

Insulet sells primarily to people with insulin-dependent diabetes, with demand driven by patients transitioning from multiple daily injections or older pump systems to Omnipod. It also serves payors, distributors, clinicians, and pharmacies that influence access, reimbursement, onboarding, and ongoing adherence. A smaller customer base consists of Amgen for drug-delivery pods used in the Neulasta Onpro kit.

- **Insulin-dependent diabetes patients** (primary) — Buy Omnipod 5 or Omnipod DASH to replace injections or tubed pumps and improve convenience.
- **Payors and health plans** (primary) — Influence access and reimbursement by evaluating the clinical and economic value of Omnipod.
- **Pharmacy and distributor channel** (secondary) — Buys and fulfills recurring pod orders, supporting scale and patient retention.
- **Clinicians and diabetes educators** (secondary) — Support adoption through training, onboarding, and patient education.
- **Amgen** (emerging) — Buys pods for the Neulasta Onpro kit, a small non-diabetes revenue stream.

- People with insulin-dependent diabetes using Omnipod instead of injections
- Patients switching from MDI therapy or tubed pumps to a patch pump
- Payors and insurers that approve coverage and reimburse Omnipod
- Pharmacies and distributors that fulfill recurring pod orders
- Clinicians and diabetes educators who train and support new users
- Amgen for pods used in the Neulasta Onpro drug-delivery kit

## Geography

Insulet generated most revenue in the United States, with international markets contributing a meaningful and fast-growing share. Management highlighted launches and rollouts of Omnipod 5 in Australia, Canada, the Nordics, France, and additional markets, while manufacturing expansion includes Costa Rica and Malaysia. The business is exposed to currency, trade, and supply-chain risks because it relies on international suppliers, a contract manufacturer in China, and overseas manufacturing capacity.

- **United States** (71%) — 2025 revenue from U.S. sales of Omnipod products.
- **International** (28%) — 2025 revenue from international Omnipod markets.
- **Drug Delivery** (1%) — Primarily sales to Amgen for Neulasta Onpro.

- U.S. is the largest market and the main revenue driver
- International revenue is growing faster than the U.S. on Omnipod 5 launches
- Omnipod 5 rollout includes Australia, Canada, the Nordics, and France
- Manufacturing expansion includes Costa Rica and Malaysia
- Supply chain exposure includes third-party suppliers and a contract manufacturer in China

## Strategy

Insulet is focused on expanding Omnipod adoption, especially through Omnipod 5 conversions and new customer acquisition in the U.S. and abroad. It is also investing in manufacturing capacity, supply-chain resilience, and cloud-based capabilities to support growth, improve service, and scale globally.

- **Expand Omnipod 5 adoption** (short-term) — Recurring pod revenue depends on adding users and converting existing patients to the latest platform.
- **Scale global manufacturing and supply chain** (medium-term) — Growth requires enough capacity, quality control, and logistics to meet demand without service disruptions.
- **Improve customer retention and onboarding** (short-term) — Retention is critical because most revenue comes from recurring pod usage after initial adoption.

- Grow Omnipod 5 adoption through new users and conversions from older systems
- Expand internationally through new market launches and broader rollout
- Increase manufacturing capacity in Costa Rica and Malaysia
- Invest in cloud-based capabilities to support customer and operational scale
- Strengthen training, support, and reimbursement to improve retention

## Risks

Insulet is highly dependent on the Omnipod platform, so any product performance issue, competitive loss, or reimbursement setback could materially affect revenue. Growth also increases operational complexity across manufacturing, logistics, and international expansion, while IT and cybersecurity risks matter because the company handles sensitive medical and financial data. Foreign exchange, trade, supplier concentration, and leadership transitions add further execution risk.

- **Dependence on Omnipod platform** [critical] — Nearly all revenue comes from one product family, so any slowdown in adoption or retention would directly reduce sales.
- **Competitive pressure in diabetes devices** [high] — The company competes with MDI therapy, smart pens, tubed pumps, and emerging patch pumps.
- **International and foreign exchange exposure** [medium] — A growing share of revenue comes from outside the U.S., creating currency and regulatory exposure.
- **Supply chain and manufacturing disruption** [high] — The company relies on outside vendors, overseas suppliers, and manufacturing sites in multiple countries.
- **Cybersecurity and IT systems failure** [high] — Systems process sensitive medical, financial, and customer data and support core operations.

- Heavy dependence on Omnipod means product or adoption setbacks hit revenue directly
- Competition from MDI, smart pens, tubed pumps, and patch pumps can pressure share
- International expansion adds currency, trade, and regulatory complexity
- Supply-chain and manufacturing disruptions could delay deliveries and raise costs
- Cybersecurity or IT failures could disrupt operations and expose sensitive data
- Leadership changes and rapid growth can strain execution and retention

## Accounting

The most important accounting judgments are revenue recognition for recurring pod sales, pharmacy rebates, and related-party sales, which can affect timing and net revenue. Investors should also watch inventory reserves, product warranty estimates, and income tax judgments, since these can move with growth, channel mix, and international expansion. Capitalized software, manufacturing investments, and debt refinancing also affect reported cash flow and balance-sheet presentation.

- **Revenue recognition** — Revenue and gross margin
- **Pharmacy rebates** — Net sales
- **Inventory reserves and warranty** — Cost of revenue and operating profit
- **Income taxes** — Tax expense and effective tax rate
- **Capitalized software and manufacturing assets** — Operating expenses, depreciation, and cash flow

- Revenue recognition and channel mix affect timing of Omnipod sales
- Pharmacy rebates and related-party sales can change net revenue
- Inventory reserves and product warranty estimates depend on demand and quality
- Income tax judgments matter as international operations expand
- Capitalized software and manufacturing assets affect cash flow and depreciation
- Debt refinancing and convertible note repurchases affect financing cash flows

---

*Last updated: 2026-08-11T04:03:56.228997+00:00*